Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- TTR sequencing is ordered once amyloidosis is confirmed or strongly suspected, and its job is to classify hereditary versus wild-type disease so family risk can be addressed.
- Genetic counseling should accompany testing, framing variable penetrance and family implications rather than certainty.
- A pathogenic variant supports cascade screening—structured, predictive testing of at-risk relatives in an autosomal dominant pattern.
- Wild-type ATTR-CM carries no inherited risk, so cascade screening applies to hereditary disease only.
What TTR Genetic Testing Does and Does Not Establish
Genetic testing in ATTR-CM answers one main question: whether the transthyretin amyloidosis is hereditary or wild-type. A detected pathogenic TTR variant supports hereditary disease and helps classify the etiology; in a patient with confirmed ATTR-CM, the absence of a pathogenic TTR variant supports a wild-type classification. What testing doesn't do is quantify myocardial amyloid burden, define symptom severity, or predict near-term trajectory. The etiologic meaning of a variant—including penetrance and how a positive or negative result should be interpreted—requires appropriate genetic counseling.
When to Offer TTR Sequencing
Sequencing is generally offered once transthyretin amyloidosis is confirmed or strongly suspected through the diagnostic pathway because the result is particularly important for family counseling and may also inform the broader clinical context. It’s particularly relevant when features suggest hereditary disease—younger age at onset, neurologic involvement, or a suggestive family history—but classifying every confirmed case as ATTRv or ATTRwt is useful because only hereditary disease has implications for relatives.
Genetic Counseling Frames Probability, Not Certainty
Counseling is part of responsible testing, both before and after the result. Pre-test counseling sets expectations about what the result can and can't tell the patient and family; post-test counseling interprets the finding in light of variable penetrance, meaning a shared variant doesn't guarantee the same age of onset or severity across a family. Coordination with genetic counseling and, where available, a specialized amyloidosis center helps ensure that results are communicated accurately and that relatives understand what predictive testing would and would not establish.
Cascade Screening Extends to At-Risk Relatives
When a pathogenic TTR variant is identified, cascade screening offers predictive testing to at-risk relatives, working outward through the family in the autosomal dominant pattern. The goal is to identify at-risk relatives and, for carriers, support appropriate clinical follow-up over time rather than imply immediate treatment of asymptomatic individuals. This is also where the wild-type distinction matters most: because ATTRwt isn't inherited, cascade screening doesn't apply, and the family conversation can be reframed accordingly.
Practical Checklist for Testing and Counseling
Before and after TTR genetic testing, confirm:
- Is transthyretin amyloidosis confirmed or strongly suspected before sequencing?
- Has pre-test counseling addressed what the result can and can't establish?
- Does post-test counseling frame variable penetrance and uncertainty?
- If a variant is found, has cascade screening of at-risk relatives been discussed?
- If wild-type, has the absence of inherited family risk been clearly communicated?
Clinical Decision Point
Genetic testing is most useful when its purpose is clear in advance: to classify hereditary versus wild-type disease and to decide whether family screening is warranted. The decision isn't whether genetic testing should establish the ATTR-CM diagnosis; its role is to determine whether a hereditary cause is present and whether family screening is warranted.
Frequently Asked Questions
Who should have TTR genetic testing in ATTR-CM?
Testing is generally offered to patients with confirmed or strongly suspected transthyretin amyloidosis to classify hereditary versus wild-type disease. It’s especially relevant with younger onset, neurologic involvement, or a suggestive family history, where hereditary disease and family implications are more likely.
What’s cascade screening?
Cascade screening is structured, predictive genetic testing of at-risk relatives after a pathogenic TTR variant is identified in a patient. It works outward through the family in the autosomal dominant pattern, aiming for awareness and appropriate surveillance of carriers rather than immediate treatment.
If the TTR test is negative, is cascade screening still needed?
In a patient with confirmed ATTR-CM, if no pathogenic TTR variant is identified, the findings support wild-type ATTR-CM, and predictive TTR testing of relatives is generally not indicated. If the clinical or family history remains suggestive of hereditary disease, appropriate genetics evaluation may still be warranted.
Why is counseling important before testing?
Pre-test counseling is important because a positive result has significant family implications and is interpreted against variable penetrance. Counseling sets expectations about what the test can establish, supports informed consent, and prepares the patient for conversations with relatives if a variant is found.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review. Biomedicines
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation Heart Failure
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.